FGL Research Reference

No human dosing protocol is established; published work uses species-specific preclinical regimens

Frequency / timing

Study-specific

Duration / setting

Study-specific

Technique

IP or SC

Evidence

No established protocol

Context: preclinical NCAM-mimetic literature

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.

No route-specific amount established in the reviewed record.

Technique

IP

Evidence

Route noted; protocol not established

Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.

Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.

10 mg/kg FGLs

Frequency / timing

Once

Duration / setting

Single-dose pharmacokinetic/behavioral study

Technique

Single SC injection in non-human primates

Evidence

Preclinical protocol

Context: Six previously untreated monkeys received FGLs in 0.9% saline

Formulation: FGLs diluted in 0.9% saline for an animal experiment

Route safety: Non-human-primate exposure only. It is not a human dose and cannot be converted to IV, oral, or another route.

25-2000 mg/kg/day

Frequency / timing

Once daily

Duration / setting

2-3 days for escalation; 7 days at the fixed dose

Technique

IV bolus in a rat dose-range/toxicity program

Evidence

Preclinical toxicity exposure

Context: European translational-development toxicity program, not an efficacy protocol

Formulation: Experimental FGLs IV preparation

Route safety: Animal toxicity-testing exposure, not an efficacy dose or human protocol. Do not convert this unusually high range to any other route.